Nurix Therapeutics, Inc. (NASDAQ:NRIX) stock is up during Monday’s premarket session as the company collaborates with Roche Holdings AG (OTC:RHHBY) to co-develop and co-commercialize bexobrutideg, an investigational Bruton’s Tyrosine Kinase (BTK) degrader.
The partnership aims to enhance treatment options for patients with B-cell malignancies, a sector projected to grow significantly, with the combined market expected to reach $41 billion by 2031.
The collaboration with Roche will focus on bexobrutideg, which is set to enter Phase 3 clinical trials for treating chronic lymphocytic leukemia (CLL) in the summer of 2026.
The partnership is seen as a strategic move to leverage Roche’s strengths in hematology and expand Nurix’s pipeline into immunology and neurology.
Deal Terms